Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease

被引:287
作者
Scott, Lauren E. [1 ]
Orvig, Chris [1 ]
机构
[1] Univ British Columbia, Dept Chem, Med Inorgan Chem Grp, Vancouver, BC V6T 1Z1, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
AMYLOID-BETA-PEPTIDE; BLOOD-BRAIN-BARRIER; PYRIDOXAL ISONICOTINOYL HYDRAZONE; IRON-CHELATION-THERAPY; TRANSGENIC MOUSE MODEL; ALZHEIMER A-BETA; OXIDASE INHIBITOR DRUGS; CENTRAL-NERVOUS-SYSTEM; HYDROGEN-PEROXIDE; WILSONS-DISEASE;
D O I
10.1021/cr9000176
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A study was conducted to demonstrate medicinal inorganic chemistry approaches to passivation and removal of abberant metal ions in disease. The study addressed the future of the design and utility of metal chelating drugs for disease therapy and focused on the development of therapeutics for amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (TSEs), cancer, and malaria. It was revealed that the most common medicinal application of metal chelators was in the treatment of metal overload conditions. The introduced metal-binding therapeutic needed to participate in a series of ligand exchange reactions to form the new desired complex before achieving metal ion repartitioning or removal.
引用
收藏
页码:4885 / 4910
页数:26
相关论文
共 331 条
  • [21] Neurodegenerative diseases and oxidative stress
    Barnham, KJ
    Masters, CL
    Bush, AI
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) : 205 - 214
  • [22] Barton JC, 2007, IDRUGS, V10, P480
  • [23] Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Aβ(142) toxicity
    Bartov, O
    Sultana, R
    Butterfield, DA
    Atlas, D
    [J]. BRAIN RESEARCH, 2006, 1069 (01) : 198 - 206
  • [24] Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators
    Bebbington, D
    Dawson, CE
    Gaur, S
    Spencer, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (22) : 3297 - 3300
  • [25] 3,5-disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone:: Potent inhibitors of lipid peroxidation and cell toxicity
    Bebbington, D
    Monck, NJT
    Gaur, S
    Palmer, AM
    Benwell, K
    Harvey, V
    Malcolm, CS
    Porter, RHP
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) : 2779 - 2782
  • [26] Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
    Becker, E
    Richardson, DR
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1999, 134 (05): : 510 - 521
  • [27] Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
    Ben Shachar, D
    Kahana, N
    Kampel, V
    Warshawsky, A
    Youdim, MBH
    [J]. NEUROPHARMACOLOGY, 2004, 46 (02) : 254 - 263
  • [28] THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS
    BENSHACHAR, D
    ESHEL, G
    FINBERG, JPM
    YOUDIM, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) : 1441 - 1444
  • [29] INTRANIGRAL IRON INJECTION INDUCES BEHAVIORAL AND BIOCHEMICAL PARKINSONISM IN RATS
    BENSHACHAR, D
    YOUDIM, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 1991, 57 (06) : 2133 - 2135
  • [30] Desferrithiocin analogues and nephrotoxicity
    Bergeron, Raymond J.
    Wiegand, Jan
    McManis, James S.
    Bharti, Neelam
    Singh, Shailendra
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (19) : 5993 - 6004